BENEFIT Extension Study
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Interferon beta-1b
Interferon alpha/beta receptor agonist
What it measured
Main measures
To obtain further clinical data of patients with a first demyelinating event suggestive of Multiple Sclerosis enrolled in the BENEFIT Study
End of Study
Who could take part
Early (CIS/RIS) · 23 to 50
Inclusion Criteria: * All patients randomized and treated at least once in study 304747 Exclusion Criteria: * Medical, psychiatric or other conditions that compromise the patient's ability to understand the purpose of the study
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.
Papers
Results
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.Mult Scler · 2014
Results
Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT.J Neurol Neurosurg Psychiatry · 2014
Loading reviews and guidelines…
Related trials
- ORACLE MS
Phase 3 · Completed
Met its main goal
- REFLEXION
Phase 3 · Completed
Met its main goal
- Betaferon® Regulatory Post-Marketing Surveillance
Completed
No result found
- REFLEX
Phase 3 · Completed
Met its main goal
- Neuroprotection With Riluzole Patients With Early Multipl…
Phase 2 · Completed
Results posted, no main test reported
- CIS-ON
Phase 3 · Completed
Results posted, no main test reported
History
Started
Sept 2007
Main results due
Jan 2011
Finished
Jan 2011
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error